Company news

Scynexis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis

July 28, 2020

SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp

July 21, 2020

SCYNEXIS Announces One-for-Ten Reverse Stock Split

July 15, 2020

SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

June 1, 2020

SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

May 10, 2020

SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp

May 5, 2020

SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

April 20, 2020

SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement

April 12, 2020

SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital

April 8, 2020

SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

March 10, 2020

SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference

March 4, 2020

SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

February 12, 2020

SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

January 7, 2020

SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors

December 15, 2019

SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants

December 11, 2019

SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants

December 9, 2019

SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update

November 11, 2019

SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)

November 6, 2019

SCYNEXIS Announces Oral Presentation of Data from Ibrexafungerp Phase 2b DOVE Study at the 3rd ISIDOG Congress

October 30, 2019

SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date

October 23, 2019

SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program

October 9, 2019

SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

September 17, 2019

SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update

August 6, 2019

SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)

July 23, 2019

SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development

June 13, 2019

SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp

May 29, 2019

SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

April 30, 2019

SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

April 2, 2019

← Newer news releases

Calls

Decks

The 5 newest of 13 decks. Every deck is listed under its year.